The largest-ever trial of treatments for Parkinson's disease found that loevodopa is better than dopamine agonists and monoamine oxidase type B inhibitors, according to research published in The Lancet.
The study found that levodopa provided better mobility and quality of life compared with DAs and MAOBIs. This information is useful in determining treatment of newly diagnosed Parkinson's.
Although levodopa is effective, after prolonged use, some patients can develop involuntary muscle spasms known as dyskinesias. While the risk of the spams is much less with DAs and MAOBI', these treatments come with a host of side effects as well, including nausea, hallucinations and sleep disturbance.
For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to the largest-ever trial of PD treatment (PD MED), published in The Lancet.